Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple system atrophy.

Gregor K Wenning1, Carlo Colosimo, Felix Geser

  • 1Department of Neurology, University Hospital, A-6020 Innsbruck, Austria.

The Lancet. Neurology
|January 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurodegenerative diseases and environmental risk factors: an overview of the available scientific evidence.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Genetic and environmental risk factors of Parkinsonism.

Journal of neural transmission (Vienna, Austria : 1996)·2026
Same author

Outcomes predictors in patients with basilar artery occlusion and mild deficits, treated with mechanical thrombectomy: A multicenter retrospective observational study.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association·2026
Same author

Setting up an autonomic unit within the neurological department: a position statement of the European Federation of Autonomic Societies.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

A European perspective on tardive dyskinesia.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2025
Same author

Postural orthostatic tachycardia syndrome is the most frequent cardiovascular autonomic disorder following COVID-19 infection or vaccination.

Journal of neurology·2025
Same journal

Resolution of expression of concern-Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study.

The Lancet. Neurology·2026
Same journal

UCL Queen Square Institute of Neurology: 75 years of innovation.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 631.

The Lancet. Neurology·2026
Same journal

Epstein-Barr virus and multiple sclerosis: from associations to mechanisms to potential therapies.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2025; 24: 740-52.

The Lancet. Neurology·2026
Same journal

Correction to Lancet Neurol 2026; 25: 357-67.

The Lancet. Neurology·2026
See all related articles

Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by parkinsonian, autonomic, and cerebellar symptoms. Recent advances in understanding alpha-synucleinopathy are improving diagnosis and paving the way for new clinical trials.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Clinical Neurology

Background:

  • Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder.
  • Clinically presents with parkinsonian, autonomic, cerebellar, or pyramidal signs.
  • Pathologically defined by cell loss, gliosis, and glial cytoplasmic inclusions.

Purpose of the Study:

  • To review recent advances in the molecular pathogenesis of MSA.
  • To highlight improvements in clinical recognition and diagnostic criteria.
  • To discuss current therapeutic strategies and ongoing clinical trials.

Main Methods:

  • Review of recent scientific literature on MSA.
  • Analysis of advances in molecular pathogenesis.
  • Evaluation of diagnostic criteria and therapeutic advancements.

Related Experiment Videos

Main Results:

  • MSA is established as an alpha-synucleinopathy.
  • Clinical recognition and diagnostic criteria have significantly improved.
  • Limited symptomatic treatments exist, but neuroprotective agents are in clinical trials.

Conclusions:

  • Understanding MSA as an alpha-synucleinopathy is crucial.
  • Improved diagnostic criteria aid in early identification.
  • Ongoing research offers hope for effective neuroprotective therapies.